# SenoRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senorx

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.senorx.com
- Total disclosed funding: $19M
- Latest round: Series C (Jun 1, 2001)
- Investors on record: 4

## About

SenoRx, Inc. is a medical technology company focused on developing innovative imaging systems and minimally invasive surgical tools to enhance patient care and improve clinical outcomes in healthcare settings.SenoRx, Inc. is a medical device company specializing in advanced imaging systems and surgical tools. Founded in 1998 and headquartered in Irvine, US, it was acquired by C.R. Bard in July 2010 for USD 200 mn after raising USD 44 mn in an IPO in March 2007. The company has completed a total of 9 deals to date.SenoRx, Inc. specializes in innovative medical technology solutions aimed at enhancing patient care and improving clinical outcomes. The company's core offerings include advanced imaging systems and minimally invasive surgical tools for use in various healthcare settings. These products address critical medical needs such as increasing diagnostic precision and facilitating quicker patient recovery. SenoRx primarily serves hospitals, outpatient surgical centers, and specialized clinics across North America and Europe, focusing on user-friendly designs and robust functionality to meet the diverse needs of healthcare providers and patients.In 2009, SenoRx, Inc. reported a revenue of USD 55.58 mn, with an EBITDA of USD -1.18 mn for the same year. The company generates revenue through direct sales of its medical devices and equipment to healthcare institutions, fostering B2B relationships. Various pricing plans are offered based on product complexity, alongside a subscription model for software updates and maintenance, which enhances revenue stability through recurring income streams related to their imaging systems and surgical tools.SenoRx, Inc. plans to leverage its recent funding from the acquisition to design and launch new advanced imaging products targeted for release in upcoming years. The company aims to expand its market presence in the European and Asian healthcare sectors by 2025. The funding from the IPO and subsequent acquisition will support these strategic initiatives, allowing SenoRx to innovate and enhance its product offerings, thereby solidifying its position within the medical technology sector.

## Funding rounds

- Series C, Jun 1, 2001, $19M — Domain Associates, Mayfield Fund, MPM BioImpact, CIT Group

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series C
- Mayfield Fund (https://capitalatlas.ai/funds/mayfield-fund) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C
- CIT Group (https://capitalatlas.ai/funds/cit-group) — Series C